Patents by Inventor Ulrich Abel
Ulrich Abel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130331573Abstract: Process for preparing piperazine of the formula I by reacting diethanolamine (DEOA) of the formula II with ammonia in the presence of hydrogen and a supported, metal-containing catalyst has been found, wherein the catalytically active mass of the catalyst, prior to its reduction with hydrogen, comprises oxygen-containing compounds of aluminum, copper, nickel and cobalt and in the range from 0.2 to 5.0% by weight of oxygen-containing compounds of tin, calculated as SnO, and the reaction is carried out in the liquid phase at an absolute pressure in the range from 160 to 220 bar, a temperature in the range from 180 to 220° C., using ammonia in a molar ratio to DEOA used of from 5 to 25 and in the presence of 0.2 to 9.0% by weight of hydrogen, based on the total amount of DEOA used and ammonia.Type: ApplicationFiled: June 5, 2013Publication date: December 12, 2013Inventors: Roland Bou Chedid, Johann-Peter Melder, Ulrich Abel, Roman Dostalek, Nina Challand, Bernd Stein, Michael Jödecke
-
Publication number: 20130331574Abstract: Process for preparing piperazine of the formula I by reacting diethanolamine (DEOA) of the formula II with ammonia (NH3) in the presence of hydrogen and a supported, metal-containing catalyst, wherein the catalytically active mass of the catalyst, prior to its reduction with hydrogen, comprises 20 to 85% by weight of oxygen-containing compounds of zirconium, calculated as ZrO2, 1 to 30% by weight of oxygen-containing compounds of copper, calculated as CuO, 14 to 70% by weight of oxygen-containing compounds of nickel, calculated as NiO, and 0 to 5% by weight of oxygen-containing compounds of molybdenum, calculated as MoO3, and the reaction is carried out in the liquid phase at an absolute pressure in the range from 160 to 220 bar, a temperature in the range from 180 to 220° C., using ammonia in a molar ratio to DEOA used of from 5 to 20 and in the presence of 0.2 to 9.0% by weight of hydrogen, based on the total amount of DEOA used and ammonia.Type: ApplicationFiled: June 5, 2013Publication date: December 12, 2013Inventors: Roland Bou Chedid, Johann-Peter Melder, Ulrich Abel, Roman Dostalek, Nina Challand, Bernd Stein, Michael Jodecke
-
Publication number: 20130324731Abstract: Process for the preparation of a mono-N-alkylpiperazine of the formula I in which R1 is C1- to C5-alkyl or 2-(2-hydroxyethoxy)ethyl, by reacting diethanolamine (DEOA) of the formula II with a primary amine of the formula H2N—R1 (III) in the presence of hydrogen and a catalyst molding, where the reaction is carried out in the liquid phase at an absolute pressure in the range from 150 to 250 bar and the amination is carried out by means of a catalyst molding, the precursor of which can be prepared according to a process in which (i) an oxidic material comprising copper oxide, aluminum oxide and lanthanum oxide is provided, (ii) pulverulent metallic copper and/or copper flakes and optionally graphite is added to the oxidic material, (iii) the mixture resulting from step ii is shaped to give a molding, where the oxidic material is obtainable by simultaneous or successive precipitation of the component copper oxide, of the component aluminum oxide and of the component lanthanum oxide and subsequent drType: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventors: Roland Bou Chedid, Johann-Peter Melder, Ulrich Abel, Roman Dostalek, Bernd Stein
-
Publication number: 20130324732Abstract: Process for the preparation of a mono-N-alkylpiperazine of the formula I in which R1 is C1- to C5-alkyl or 2-(2-hydroxyethoxy)ethyl, by reacting diethanolamine (DEOA) of the formula II with a primary amine of the formula H2N—R1 (III) in the presence of hydrogen and a supported, metal-containing catalyst, where the catalytically active mass of the catalyst, prior to its reduction with hydrogen, comprises oxygen-containing compounds of aluminum, copper, nickel and cobalt and, in the range from 0.2 to 5.0% by weight, oxygen-containing compounds of tin, calculated as SnO, and the reaction is carried out in the liquid phase at an absolute pressure in the range from 95 to 145 bar.Type: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventors: Roland Bou Chedid, Johann-Peter Melder, Ulrich Abel, Roman Dostalek, Bernd Stein
-
Publication number: 20130289090Abstract: Substituted indole derivatives of formula (I) wherein the radicals have e.g. the following meaning: R1 is hydrogen, C1-6-alkyl, R2 is hydrogen, —C1-6-alkyl or cycloC3-12-alkyl; R3 is OR R4 is hydrogen or halogen, R5 is hydrogen, —C1-6-alkyl R6 is hydrogen, —C1-6-alkyl R is hydrogen or —C1-6-alkyl; X is a group —C(O)CH2— or —CH?CH—; R7 is hydrogen are potent inhibitors of Abeta peptide polymerization and can be used for the treatment of e.g. Alzheimers disease or ocular disorders.Type: ApplicationFiled: October 27, 2011Publication date: October 31, 2013Applicant: MERZ PHARMA GMBH & CO. KGAAInventor: Ulrich Abel
-
Patent number: 8524911Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.Type: GrantFiled: May 16, 2012Date of Patent: September 3, 2013Assignee: Merck Serono SAInventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
-
Publication number: 20130225512Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.Type: ApplicationFiled: November 15, 2011Publication date: August 29, 2013Applicant: Merz Pharma GmbH & Co. KGaAInventors: Ehud Gazit, Yaniv Amir, Ludmila Buzhansky, Ulrich Abel, Anat Frydman-Marom
-
Publication number: 20120295856Abstract: The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Applicant: ZENTOPHARM GmbHInventors: Ulrich Abel, Werner Simon
-
Publication number: 20120295889Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: Merck Serono S.A.Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
-
Publication number: 20120232116Abstract: The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.Type: ApplicationFiled: August 19, 2010Publication date: September 13, 2012Applicant: PHENEX PHARMACEUTICALS AGInventors: Claus Kremoser, Ulrich Abel, Christoph Steeneck, Olaf Kinzel
-
Patent number: 8247424Abstract: The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.Type: GrantFiled: March 20, 2003Date of Patent: August 21, 2012Assignee: Zentopharm GmbHInventors: Ulrich Abel, Werner Simon
-
Patent number: 8236818Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.Type: GrantFiled: March 28, 2008Date of Patent: August 7, 2012Assignee: Santhera Pharmaceuticals (Schweiz) AGInventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
-
Patent number: 8198457Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.Type: GrantFiled: May 20, 2011Date of Patent: June 12, 2012Assignee: Merck Serono S.A.Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
-
Patent number: 8193192Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.Type: GrantFiled: August 29, 2007Date of Patent: June 5, 2012Assignee: Phenex Pharmaceuticals AGInventors: Claus Kremoser, Ulrich Deuschle, Ulrich Abel, Andreas Schulz
-
Publication number: 20110263046Abstract: The invention relates to modulators for the orphan nuclear receptor RORgamma and methods for identification and screening of novel modulators for RORgamma activity as well as methods for treating RORgamma mediated diseases with novel RORgamma modulators identified by such methods.Type: ApplicationFiled: October 28, 2009Publication date: October 27, 2011Applicant: PHENEX PHARMACEUTICALS AGInventors: Ulrich Deuschle, Ulrich Abel, Claus Kremoser, Thomas Schlueter, Thomas Hoffmann, Sanja Perovic-Ottstadt
-
Publication number: 20110224192Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: May 20, 2011Publication date: September 15, 2011Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
-
Patent number: 7956191Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.Type: GrantFiled: October 19, 2005Date of Patent: June 7, 2011Assignee: Merck Serono SAInventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
-
Publication number: 20100210660Abstract: The present invention relates to compounds which bind to the NRI H4 receptor (FXR) and act as agonists or partial agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.Type: ApplicationFiled: August 29, 2007Publication date: August 19, 2010Applicant: PHENEX PHARMACEUTICALS AGInventors: Claus Kremoser, Ulrich Deuschle, Ulrich Abel, Andreas Schulz
-
Publication number: 20100184809Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.Type: ApplicationFiled: August 29, 2007Publication date: July 22, 2010Applicant: PHENEX PHARMACEUTICALS AGInventors: Claus Kremoser, Ulrich Deuschle, Ulrich Abel, Andreas Schulz
-
Patent number: RE43760Abstract: A method and apparatus are disclosed for adjusting the bandwidth of a connection between at least two communication endpoints in a data network via a monitoring unit and a control unit. The connection in the data network is assigned at least one transmission channel for data transmission. The user data is, in this case, allocated to at least one communication connection; in particular a voice connection. The monitoring unit monitors the signaling connection for requests for at least one further communication connection; in particular, a voice connection. When a request occurs, it signals to the control unit to assign to the connection one or more additional free transmission channels for the at least one requested communication connection.Type: GrantFiled: May 1, 2009Date of Patent: October 23, 2012Inventors: Ulrich Abel, Norbert Schoenfeld, Werner Lindemann